Clinical trials: Progress-free Survival
Progress-free Survival, Overall Response Rate
Study for HER2-Overexpressed MBC Patients Treated by Cipterbin® Plus vinorelbinE
Breast cancer is the most common malignant disease and the most frequent causes of cancer mortality in females worldwide. The situation is same as the world in China.
- Conditions
- Progress-free Survival, Overall Response Rate, Adverse Events
- Trial name
- HOPES (NCT01291667)
- Volunteers
- 330 people
- Sponsor
- Shanghai CP Guojian Pharmaceutical Co., Ltd.
Locally Advanced Malignant Neoplasm
Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer
For patients resistant to enthrycycline and taxanes, there is no standard regimen. Pemetrexed alone had certain efficacy in treatment of advance breast cancer. Platin was also a effective drug for advanced breast cancer.
- Trial name
- NCT01143974
- Testing
- pemetrexed plus cisplatin
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Chinese Academy of Medical Sciences
Adenocarcinoma of the Prostate
A Prospective Randomized Phase III Study Comparing Hormonal Therapy +/-Docetaxel
The primary objective was to evaluate the PSA (biochemical) progression-free survival (PFS) of high-risk metastasis-free PC patients, treated with LH-RH agonist for one year with or without docetaxel after prior radical…
- Trial name
- RisingPSA (NCT00764166)
- Testing
- Docetaxel + hormonal treatment (LH-RH agonist), Hormonal treatment (LH-RH agonist)
- Where
- France
- Volunteers
- 254 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Progress Free Survival (PFS) and Overall Survival (OS)
Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma
The aie of this clinical study is the safety and efficacy of combination therapy for HCC patients.
- Trial name
- NCT04393220
- Testing
- Bevacizumab Injection, Nivolumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Non-Small Cell Lung Cancer (NSCLC)
Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC
According to literature reports, about 16.3%-19% of newly diagnosed NSCLC patients are associated with brain metastasis, and 30%-50% of NSCLC patients will develop brain metastasis during the whole course of the disease.
- Trial name
- NCT04905550
- Testing
- Almonertinib, Stereotactic Radiotherapy(SRT) or Stereotactic Radiosurgery(SRS) or Whole-Brain Radiotherapy(WBRT)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Chongqing University Cancer Hospital
Breast Cancer
Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.
The purpose of this study is to complement Study CBYL719C2301 (SOLAR-1) and obtain more comprehensive data on the efficacy and safety of alpelisib (BYL719) in combination with fulvestrant compared with placebo plus fulvestrant in…
- Trial name
- EPIK-B5 (NCT05038735)
- Testing
- Alpelisib, Fulvestrant
- Where
- 68 sites in Belgium, Bulgaria and 15 more
- Volunteers
- 210 people
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor Cancer, Metastases
Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors
This study evaluates a non-cationic peptide-CD47 siRNA nanocomplex for refractory advanced solid tumors. The candidate blocks the CD47-SIRPα "don't eat me" signal, repolarizes tumor-associated macrophages, and restores antitumor…
- Conditions
- Solid Tumor Cancer, Metastases, Head and Neck Cancer
- Trial name
- NCT07583914
- Testing
- NCP-CD47 siRNA intratumorally injection
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Gastric Carcinoma
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests.
- Trial name
- NCT00970138
- Testing
- apatinib tablet
- Where
- China
- Volunteers
- 141 people
- Sponsor
- Fudan University
Metastatic Breast Cancer
Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer
The goal of the study is to understand the meaning of progression-free survival for women with metastatic breast cancer and to use this understanding to create and distribute a new questionnaire to assess the effect progression…
- Trial name
- NCT01282931
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Health Outcomes Solutions
Breast Cancer
THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.
This 2 arm study will compare the efficacy and safety of continuation or discontinuation of Herceptin treatment in combination with 2nd line chemotherapy, in patients with HER2 positive metastatic breast cancer whose condition…
- Trial name
- NCT00448279
- Testing
- trastuzumab, Chemotherapy
- Where
- 35 sites in Italy
- Volunteers
- 58 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine)as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer
This randomized study will compare maintenance therapy with Avastin (bevacizumab) + Xeloda (capecitabine) versus Avastin alone, in patients with HER2-negative metastatic breast cancer who have not progressed during first-line…
- Trial name
- NCT00929240
- Testing
- bevacizumab [Avastin], capecitabine [Xeloda]
- Where
- 63 sites in Brazil, China and 9 more
- Volunteers
- 287 people
- Sponsor
- Hoffmann-La Roche